Dementia's Growing Economic and Health Challenge in Sweden: Costs, Treatments, and Prevention

Dementia, or cognitive diseases as now preferred in medical terms, poses a significant and rising challenge in Sweden, impacting approximately 130,000 to 160,000 people. The societal costs are currently estimated around SEK 90-100 billion annually, with projections indicating an increase of about 80% by 2050 due to demographic shifts. This economic burden is primarily shouldered by municipalities, responsible for about 85% of costs, largely relating to residential care.

In parallel with financial concerns, dementia leads to marked reductions in life expectancy and quality of life for patients and their families. Recent health economic analyses highlight the crucial need to evaluate the cost-effectiveness of emerging treatments, particularly antibody therapies for Alzheimer's disease like lekanemab and donanemab. However, current uncertainties remain as these treatments' prices are not yet established, complicating formal cost-benefit assessments. The integration of new diagnostic tools, including blood-based biomarkers, is viewed as promising for improving diagnosis accuracy and supporting economic evaluations.

Sweden is at the forefront of research on dementia prevention, diagnosis, and treatment, emphasizing early interventions. Cognitive diseases develop over long periods, with brain changes potentially occurring two decades before symptoms manifest. Research suggests that nearly 45% of cognitive diseases can be attributed to modifiable health, behavioral, and environmental factors, underscoring the importance of prevention. The national dementia strategy, "Every Day Counts" (2025-2028), advocates for preventive healthcare and multimodal lifestyle programs mirroring successful international models like the FINGER intervention.

Advances in biomarkers and imaging technologies have shifted diagnostic approaches from exclusion to specific disease identification and treatment monitoring. The advent of disease-modifying treatments targeting amyloid proteins represents a move toward precision medicine, necessitating enhanced coordination between specialists and primary care providers.

Going forward, systematic follow-ups on treatment effectiveness, alongside continued economic evaluations, are essential to ensure the sustainability of dementia care. Additionally, prevention programs focusing on lifestyle changes have demonstrated cost-effectiveness, potentially delaying cognitive decline and easing future economic strain.

Overall, dementia's impact in Sweden encompasses profound health and economic dimensions. Continued innovation, combined with strategic healthcare adaptation and preventive measures, offers hope for mitigating the growing challenges posed by cognitive diseases.